60 degrees pharmaceuticals receives fda comments on tafenoquine-babesiosis clinical trial protocol; no material changes required

Trial planning and execution to proceed as planned washington, may 02, 2024 (globe newswire) -- 60 degrees pharmaceuticals, inc.  (nasdaq: sxtp ; sxtpw) (the “company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the u.s. food and drug administration (fda) has provided comments on the protocol of a planned clinical trial that will study the use of tafenoquine in treating babesiosis. babesiosis, a potentially life-threatening disease in immunosuppressed patients, is a tick-borne illness steadily emerging in the united states.
SXTP Ratings Summary
SXTP Quant Ranking